MedTrace Logo

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

NCT00160654 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2020-08-19

Study results available
· View outcomes & findings →

Summary

Community based study assessing safety and efficacy of levetiracetam in partial onset seizures.

The optimal dose in daily clinical practice will be used.

Conditions

  • Epilepsy, Partial

Interventions

DRUG

Levetiracetam

* Pharmaceutical form: oral tablets * Concentration: 500 mg * Route of administration: Oral use

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Cares · UCB (+1 844 599 2273)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-24
Primary Completion
2006-12-12
Completion
2006-12-12

Countries

  • Hong Kong
  • Malaysia
  • Philippines
  • Singapore
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160654 on ClinicalTrials.gov